The oncology clinical trials market size is expected to reach USD 16.63 billion by 2028 according to a new study by Polaris Market Research. The report “Oncology Clinical Trials Market Share, Size, Trends, Industry Analysis Report, By Phase (Phase I, Phase II, Phase III, Phase IV); By Study Design (Interventional, Observational, Expanded Access); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa); By Cancer Type; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Pancreatic cancer has a poor prognosis of just 1 to 3 years of survival. In a day, about 16 people were suffering from intestinal stromal tumors and around 60,000 new cases of renal carcinoma were observed in the U.S alone. The factors listed above reflect a growing incidence of cancer and an increasing need for successful care for different forms of cancer. Study on cancer care is going ahead at a rapid rate.
A change from chemotherapy protocols to molecularly targeted immunotherapy agents has been observed. Cancer continues to present new problems and opportunities for pharmacological action. As a result, the pharmaceutical industry continues to produce oncology drugs at an unprecedented pace.
Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/oncology-clinical-trials-market/request-for-sample
In Asia Pacific, the market demand for oncology clinical trials is expected to witness the fastest growth over the forecast period, due to the growing availability of a wide patient pool to promote the recruitment of candidates. According to Asia Pacific’s largest expert biotech company CRO. The area has become the chosen destination for clinical studies due to the low density of the trial and a large number of active investigators.
Many biotechnological companies pursuing CRO oncology services are increasingly turning to this field. For example, the EMA issued guidelines for accelerating the evaluation of qualifying medicines in 2015. In 2016, the Priority Medicines (PRIME) scheme was introduced to identify certain drugs at an early stage of production that has the potential to meet unmet medical needs.
Market participants operating in the oncology clinical trials industry include PAREXEL International Corporation, PRA Health Sciences, Syneos Health, Medpace, Novotech, Pivotal, ICON Plc, Wuxi AppTec, Eli Lilly and Company, Novo Nordisk A/S, Pfizer, and Clinipace.
Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/oncology-clinical-trials-market/request-for-discount-pricing
Polaris Market Research has segmented the oncology clinical trials market report on the basis of phase, study design, cancer type, and region:
Oncology Clinical Trials, Phase Outlook (Revenue – USD Million, 2016 – 2028)
- Phase I
- Phase II
- Phase III
- Phase IV
Oncology Clinical Trials, Study Design Outlook (Revenue – USD Million, 2016 – 2028)
- Interventional
- Observational
- Expanded Access
Oncology Clinical Trials, Cancer Type Outlook (Revenue – USD Million, 2016 – 2028)
- Lung cancer
- Breast cancer
- Thyroid cancer
- Leukemia
- Liver cancer
- Skin cancer
- Lymphoma
- Pancreatic cancer
- Prostate cancer
- Colon & rectal cancer
- Urinary system cancer
- Other cancer
Buy Now @ https://www.polarismarketresearch.com/checkouts/8621
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
Web: www.polarismarketresearch.com
Oncology Devices Global Market Report 2021 by The Business Research Company is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact – both negative and positive – of COVID-19 on the oncology devices industry gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
This includes revised market numbers according to the effects of the coronavirus and the expected oncology devices market growth numbers 2021-2030.View Complete Report:https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report-2020-30-covid-19-growth-and-change The Oncology Devices Global Market Report 2020-30 by The Business Research Company provides an in-depth analysis of the global oncology devices market and covers both the historic period, 2015 to 2020, and the forecast period, 2020 to 2030.
The report evaluates the market and major economies across the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.The Oncology Devices Global Market Report 2021 covers oncology devices market drivers, oncology devices market trends, oncology devices market growth rate, oncology devices market major players, player-adopted strategies in the market, and oncology devices market size.The global oncology devices market is expected to grow from $96.335 billion in 2020 to $110.44 billion in 2021 at a compound annual growth rate (CAGR) of 14.6%.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.
The market is expected to reach $196.963 billion in 2025 at a CAGR of 16%.
Community Oncology Services Global Market Report 2021 by The Business Research Company is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact – both negative and positive – of COVID-19 on the community oncology services industry gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
This includes revised market numbers according to the effects of the coronavirus and the expected community oncology services market growth numbers 2021-2030.View Complete Report:https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report-2020-30-covid-19-growth-and-changeThe Community Oncology Services Global Market Report 2020-30 by The Business Research Company provides an in-depth analysis of the global community oncology services market and covers both the historic period, 2015 to 2020, and the forecast period, 2020 to 2030.
The report evaluates the market and major economies across the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.The Community Oncology Services Global Market Report 2021 covers community oncology services market drivers, community oncology services market trends, community oncology services market growth rate, community oncology services market major players, player-adopted strategies in the market, and community oncology services market size.
The global community oncology services market is expected to decline from $70.98 billion in 2020 to $70.78 billion in 2021 at a compound annual growth rate (CAGR) of -0.3%.
The slow decline is attributed to COVID-19 restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.
According to the National Cancer Institute, cancer survival rates over a five-year period in the US have demonstrated a marked improvement to 70% in 2020 – mainly due to improved healthcare, public policy, and novel pharmaceutical therapies.
A few other common cancers include skin, pancreatic, thyroid, renal, soft tissue, and brain cancer with breast, lung, and colorectal cancer accounting for more than 50% of all diagnosis in women.
Supply Chains Enable Transformation in Autologous Therapy in Oncology Drugs MarketRNA therapy, stem cell therapy, viral vectors, and cell therapy have been the buzzwords in the oncology drugs market with gene therapies leading to evermore complex supply chain and manufacturing processes – particularly for autologous therapies.
The treatment and diagnostics regimen has progressed rapidly through precision medicine with approx.
4/5th of novel clinical assets are for marketed targets with four or more clinical competitors leading to quicker initial launches, shorter development cycles, and competitor therapies.
Maximum Activity Witnessed in Oncology With Thrice Development Spend of Other SectorsInnovation in the oncology sector has boomed with the highest number of novel FDA approvals in this dynamic field.
